Screening for multidrug-resistant organisms in high-risk hospitalized patients with hematologic diseases

Eur J Haematol. 2024 Apr;112(4):627-632. doi: 10.1111/ejh.14157. Epub 2023 Dec 20.

Abstract

Objectives: Patients treated for hematologic malignancies are at higher risk for blood stream infections (BSI) and multidrug-resistant organisms (MDRO) are increasingly involved. Studies showed a significant association between rectal colonization status and a higher risk of subsequent MDRO BSI. The objective of our study was to probe the practice of surveillance cultures in Belgian hematology centers.

Methods: A questionnaire was sent to the 13 hematology centers participating in the acute leukemia board of the Belgian Hematology Society. 21 questions probed for the method of surveillance cultures, MDRO screened, antimicrobial prophylaxis, and empirical therapy and their relationship with colonization status.

Results: All centers completed the questionnaire in full. Routine gastrointestinal surveillance cultures in hematologic patients are taken in 10 hospitals. Organisms tested for included mostly ESBL (n = 9) and carbapenem-resistant (n = 8) Enterobacterales. All centers with a screening strategy adapt empiric antibiotic therapy based on MDRO colonization. Prophylaxis strategies are variable, only two centers adapt prophylaxis upon documentation of fluoroquinolone resistance.

Conclusions: The majority of the Belgian centers perform routine surveillance cultures and adapt empiric therapy for neutropenic fever accordingly. Other reasons for testing include to gain insight into local epidemiology and to prevent in-hospital transmission. In general, there was significant variability in surveillance dimensions.

Keywords: blood stream infections; febrile neutropenia; multiple drug resistance; surveillance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Carbapenems
  • Drug Resistance, Multiple, Bacterial
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / diagnosis
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Leukemia, Myeloid, Acute*
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Carbapenems